ClinicalTrials.gg
RecruitingNCT04095572AlP-FrUiTUpdated Feb 19, 2025

Alternative Prophylaxis in Female Recurrent Urinary Tract Infections

A Phase 4 interventional study of intravesical instillation with HA-CS and intravesical instillation of sterile purified water in Urinary Tract Infections and Urinary Tract Infection (UTI), sponsored by University Hospital, Basel, Switzerland. Recruiting at 2 sites in Switzerland. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by University Hospital, Basel, Switzerland · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Urinary Tract Infections with a site in Switzerland — 4 open to participants now, 4 under way, none of them phase 3. Urinary Tract Infections · Switzerland.

Planned enrollment
12th of 15
50 · median 192
Started
2020
with 3 others
Phase 4
5 of 21
1 open now
Registered
17th of 21
by date
Lead sponsor
6 of 21
University Hospital, Basel, Switzerland

Among the 21 studies in Urinary Tract Infections with a site in Switzerland, this one is the 12th largest by planned enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2020, is one of 5 in phase 4, and was the 17th registered.

Urinary Tract Infections

808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

4 of the 21 studies in Urinary Tract Infections with a site in Switzerland are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Urinary Tract Infections with a site in Switzerland, or all of them as a file.
02

Study summary

Urological pathogens are effected by rising antimicrobial resistance rates due to the frequent use of antimicrobials for treatment and prophylaxis. Intravesical instillation with hyaluronic acid (HA) and chondroitin sulphate (CS) obtained positive outcomes in the treatment of overactive bladder, radiation cystitis and interstitial cystitis by replenishment of the glycosaminoglycan layer of the bladder. This study is to investigate whether intravesical instillation with HA-CS in patients with recurrent urinary tract infections (rUTI) is superior to a placebo instillation in terms of reduction of rate of symptomatic urinary tract infections (UTIs) (based on clinical diagnosis) needing treatment with antimicrobials within 12 months after randomisation.

03

Conditions studied

  • Urinary Tract Infections
  • Urinary Tract Infection (UTI)

Keywords

  • Hyaluronic acid (HA)
  • Chondroitin sulphate (CS)
  • antimicrobial resistance rates
  • Intravesical instillation
  • HA-CS instillations
  • Recurrent Urinary Tract Infection (rUTI)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented history of rUTI, defined as ≥ 3 episodes of (un)complicated UTI documented by urine culture with the isolation of ≥103 cfu/ml of an identified pathogen in the last year with clinical symptoms OR 2 episodes in the last 6 month

Exclusion criteria

Exclusion Criteria:

  • No
  • Concomitant UTI (\< 7 days prior to randomisation)
  • Ongoing antimicrobial prophylaxis (e.g. for rUTI or for any other reason like endocarditis, transplanted patients under )
  • Ongoing prophylactic strategy (e.g. immunoactive prophylaxis)
  • Documented underlying urogenital abnormality (e.g. significant post voiding residual volume (>50 ml), urethral stricture, urethral diverticula, urinary stone, reflux, urinary neoplasia), urological device (e.g. catheter, ureteral stent) or symptomatic pelvic floor disorder (e.g. genital prolapse stage ≥ II)
  • Concomitant disease (i.e. renal insufficiency, diabetes mellitus, use)
  • Urogenital urological or gynecological surgery \< 6 weeks
  • Known allergy to the study medication
  • Use of spermicides or intrauterine device
  • Pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    intervention group A

    50 ml of a sterile sodium HA (800 mg)- CS (1g) solution (Ialuril Prefill®, IBSA Farmaceutici Italia Srl, Via Martiri di Cefalonia 2, 26900 Lodi, Italy) weekly for four weeks, then every second week in the second month and four weeks later

    Drug: intravesical instillation with HA-CS

  • Placebo comparator
    control group B

    50 ml sterile purified water weekly for four weeks, then every second week in the second month and four weeks later

    Drug: intravesical instillation of sterile purified water

Interventions

  • Drugintravesical instillation with HA-CS

    intravesical instillation with HA-CS (Ialuril Prefill®, IBSA Farmaceutici Italia Srl, Lodi, Italy)

  • Drugintravesical instillation of sterile purified water

    intravesical instillation of sterile purified water (packed and labelled according to Good Manufacturing Practice at IBSA Farmaceutici Italia Srl in Lodi, Italy to provide adequate blinding)

06

What researchers measure

Primary outcomes

  1. Rate of symptomatic UTIs (based on clinical diagnosis) needing treatment with antimicrobials

    Rate of symptomatic UTIs (based on clinical diagnosis) needing treatment with antimicrobials (cumulative number)

    Time frame: within 12 months after randomisation

Secondary outcomes

  1. Symptomatic UTI (based on clinical diagnosis supported by measured bacteriuria of ≥103 cfu/ml) treated with antimicrobials

    Symptomatic UTI (based on clinical diagnosis supported by measured bacteriuria of ≥103 cfu/ml) treated with antimicrobials (cumulative number)

    Time frame: at screening and at each instillation visit (week 1 = Randomization, week 2, week 3, week 4, week 6, week 8, week 12) and at follow-up visits after randomization (month 6, month 9, month 12)

  2. Symptoms of UTI according to the Acute Cystitis Symptom Score (ACSS) (cumulative number of each symptom)

    Change in Acute Cystitis Symptom Score (ACSS). The first part of the ACSS questionnaire consists of 14 questions. The first 6 questions assess typical symptoms of UTI: frequency, urgency, pain and burning during urination, sensation of incomplete bladder emptying, pain/discomfort in the lower abdomen, visible hematuria. Each question concerning urinary symptoms allows the patient to choose one out of four answers indicating increasing severity of the particular symptom. The answers are assigned points from 0 to 3. The score can range between 0 and 18. It has been validated and a score ≥ 6 seems to be very indicative for the diagnosis of an UTI.

    Time frame: at screening and at each instillation visit (week 1 = Randomization, week 2, week 3, week 4, week 6, week 8, week 12) and at follow-up visits after randomization (month 6, month 9, month 12)

  3. Time to UTI recurrence (as days between randomisation and the first recurring UTI)

    Time to UTI recurrence (as days between randomisation and the first recurring UTI)

    Time frame: at screening and at each instillation visit (week 1 = Randomization, week 2, week 3, week 4, week 6, week 8, week 12) and at follow-up visits after randomization (month 6, month 9, month 12)

  4. Asymptomatic bacteriuria of ≥105 cfu/ml

    Asymptomatic bacteriuria, measured by number of colony forming Units (cfu) of ≥105 cfu/ml

    Time frame: at each instillation visit (week 1 = Randomization, week 2, week 3, week 4, week 6, week 8) if the urine dipstick is suspicious, at the 7th instillation (= week 12 )and at 12 month follow-up

  5. Detection of multidrug-resistant bacteria in urine culture (3Multiresistant gram negatives (MRGN), 4MRGN)

    Detection of multidrug-resistant bacteria in urine culture (3MRGN, 4MRGN) (yes/no)

    Time frame: at screening and at at each instillation visit (week 1 = Randomization, week 2, week 3, week 4, week 6, week 8, week 12) and at follow-up visits after randomization (month 6, month 9, month 12)

  6. Prescribed defined daily doses (DDD) of antibiotics (cumulative sum of DDD)

    Prescribed defined daily doses (DDD) of antibiotics (cumulative sum of DDD)

    Time frame: from randomisation to 12 months

  7. Change in Pelvic Pain and Urinary/Frequency (PUF) Symptom Scale

    The PUF questionnaire consists of 12 questions. The first two questions allow the patient to choose one out of five answers (points 0-3), the following questions one out of four (points 0-3) indicating increasing severity of the particular symptom. Seven of the questions concern symptoms (total count 23), four questions are part of the bother score (total count 12). Total score consists of symptom score and bother score (total count 35). The change of the score is calculated by subtracting the score at 1 month, 3 months, 6 months, 9 months, 12 months from the score at enrolment

    Time frame: prior to randomisation and at 1 month, 3 months, 6 months, 9 months, 12 months

  8. Change in QoL Short Form (SF)-36 score

    The QoL SF-36 consists of 36 items including eight independent scales and two main dimensions 35 of the items are compressed into eight multi-item scales: (1) physical functioning is a ten-question scale; (2) role-physical is a four-item scale; (3) bodily pain is a two-item scale; (4) general health is a five-item scale; (5) vitality is a four-item scale; (6) social functioning is a two-item scale; (7) role-emotional is a three-item scale; and (8) mental health is a five-item scale. Hence, in the SF-36 scoring system, the scales are assessed quantitatively, each on the basis of answers to two to ten multiple choice questions, and a score between 0 and 100 is then calculated on the basis of well-defined guidelines, with a higher score indicating a better state of health. The change of the score is calculated by subtracting the score at 12 month from the score at enrolment.

    Time frame: prior to randomisation and at 12 months

07

Study locations

2 of 2 sites recruiting
  • Department of Gynecology, University Hospital Basel
    Basel, 4031, Switzerland
    Recruiting
  • Department of Urology, University Hospital Basel
    Basel, 4031, Switzerland
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Jun 2025, 56 months after the start.

Of 45 non-industry phase 4 interventional studies under Urinary Tract Infections, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 54. This study's planned 56 months is above that.

Counting every sponsor, half of 51 studies reached it within 37 months; a quarter within 22 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2019
First posted
Sep 19, 2019
StartActual
Oct 27, 2020
Primary completionEst.
Jun 2025
CompletionEst.
Jun 2026
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04095572
Responsible party
Sponsor
First posted
Sep 19, 2019
Start date
Oct 27, 2020
Primary completion
Jun 2025 (estimated)
Completion
Jun 2026 (estimated)
Last update
Feb 19, 2025

Study contacts

Kathrin Bausch, Dr. med
Contact
kathrin.bausch@usb.ch
+41 61 265 72 80
Hans-Helge Seifert, Prof. Dr. MD
Contact
helge.seifert@usb.ch
+41 61 265 72 80
Kathrin Bausch, Dr. med
principal investigator · Department of Urology, University Hospital Basel

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion